Abstract | PURPOSE: METHODS: A total of 49 treatment-naive patients (49 eyes) with large SMH (more than five disc areas ( DAs)) secondary to nAMD were retrospectively included. All patients were treated with an initial series of 3 monthly intravitreal anti- VEGF injections, followed by as-needed injections. At the 12-month follow-up, changes in best-corrected visual acuity (BCVA), hemorrhage area, central foveal thickness, and development of vitreous hemorrhage after treatment were evaluated. RESULTS: The mean SMH area was 13.9 ± 8.8 disk areas ( DAs) and mean symptom duration was 7.25 ± 5.9 days at baseline. The mean number of injections was 4.49 ± 1.61. Twelve months after treatment, the mean BCVA significantly improved from 1.14 ± 0.61 logarithm of the minimum angle of resolution (logMAR; 20/276, Snellen equivalent) to 0.82 ± 0.53 logMAR (20/132; P = 0.002). Twenty-four eyes (49%) showed improvement of more than three lines of BCVA at 12 months after treatment. Baseline BCVA (odds ratio (OR), 5.119; 95% confidence interval (CI), 1.993-9.545; P = 0.004), duration of symptoms (OR, 0.727; 95% CI, 0.332-0.952; P = 0.024), hemorrhage area (OR, 0.892; 95% CI, 0.721-0.965; P = 0.011), and baseline central foveal thickness (OR, 0.881; 95% CI, 0.722-0.945; P = 0.032) were significantly associated with good visual acuity 12 months after treatment. CONCLUSIONS: Intravitreal anti- VEGF monotherapy is a valuable treatment option for large SMH secondary to nAMD.
|
Authors | H S Kim, H J Cho, S G Yoo, J H Kim, J I Han, T G Lee, J W Kim |
Journal | Eye (London, England)
(Eye (Lond))
Vol. 29
Issue 9
Pg. 1141-51
(Sep 2015)
ISSN: 1476-5454 [Electronic] England |
PMID | 26272443
(Publication Type: Journal Article)
|
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Vascular Endothelial Growth Factor A
- Bevacizumab
- Ranibizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(administration & dosage)
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Bevacizumab
(administration & dosage)
- Female
- Fluorescein Angiography
- Humans
- Intravitreal Injections
- Macular Degeneration
(complications, drug therapy)
- Male
- Middle Aged
- Ranibizumab
(administration & dosage)
- Retinal Hemorrhage
(drug therapy, etiology)
- Retrospective Studies
- Tomography, Optical Coherence
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
|